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SINGLE INSTILLATION OF MITOMYCIN C REDUCES 1ST YEAR
RECURRENCE FOLLOWING TRANSURETHRAL RESECTION OF
NON-MUSCLE INVASIVE BLADDER CANCER
M. Hammad Ather, S Aziz, M N Sulaiman
Department of Surgery, The Aga Khan University Hospital, Karachi, Pakistan

Objective: To study the impact of single instillation of 40 mg Mitomycin C (MMC-40) within first
hour of transurethral resection (TUR), on first year recurrence of non-muscle invasive bladder
cancer. Methods: In this study of two groups of patients with similar demographics and tumour
profile were compared to assess first year tumour recurrence pattern. Group A received MMC-40
within 30 minutes of TUR. Group B patients only had TUR of bladder tumour. Patients’ charts were
reviewed for demographic profile, preoperative diagnosis and imaging used, cytological work up,
tumour profile both during cystoscopy and imaging used, patients records were also reviewed for all
subsequent check cystoscopies for recurrence. Any adjuvant treatments like intravesical
chemo/immunotherapy etc. were also noted. The results were analysed using a commercially
available statistical package, SPSS™. The level of significance was 0.05. Results: There were 29
and 46 patients in group A and B respectively. The demographic profile in terms of age, gender
distribution, tumour characteristics (size, site, multiplicity) and pathological evaluation including,
tumour grade and presence of carcinoma in situ were similar (p<0.4 and p<0.5) respectively. The
first year recurrence rate in group A was 15% whereas it was 37.4% in group B (p<0.04).
Conclusions: The first year recurrence rate is significantly decreased if MMC-40 is instilled
following TUR. MMC-40 is safe and cost effective. Most low grade, low volume tumours would not
require any further treatment if MMC-40 is given immediately following TUR.
Key words: non-muscle invasive bladder cancer, single instillation of chemotherapeutic agent,
recurrence

INTRODUCTION
Bladder cancer is the second commonest urological
malignancy in the world1 and commonest in Pakistan.
In United States in year 2006, estimated 61420 new
cases are diagnosed.1 Majority of bladder cancers
presents as superficial transitional cell cancers.
Superficial tumours have a high rate of recurrence (2540%) in the first year2 following transurethral resection
(TUR). Following TUR intravesical treatment of either
immunotherapeutic agent, Bacillus Calmette-Guérin
(BCG), or a chemotherapeutic agent like Mitomycin C
(MMC) is considered to avoid recurrence. However, in
majority of cases it is an over treatment in patients
with low risk cancers. Transurethral resection of the
tumour is considered as treatment of choice in nonmuscle invasive bladder cancer. A number of studies
agree with the fact that intravesical instillation of
cytotoxic agents within the first hours after operation
reduces the risk of tumour recurrence.3 It is assumed
that transurethral resections of bladder tumours evoke
relevant intravesical tumour cell suspensions. Thus,
reimplantation of tumour cells and consequently a
cancer recurrence are promoted.4 In this case, early
intravesical instillations of chemotherapeutic agents
such as Mitomycin or Epirubicin have cytotoxic and
preventive effects. Side effects of intravesical
instillation are uncommon, and therefore, this therapy
is considered to be simple and safe.5 In the current
work we have looked at the efficacy, of administration
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of 40 mg of MMC in the recovery room in prevention
of 1st year recurrence of non-muscle invasive bladder
cancer.

MATERIAL AND METHODS
This is a comparative study conducted to assess the
impact of 40 mg of Mitomycin C (MMC-40) on
recurrence in the first year following TUR. Patients
were divided in two groups with similar demographic
and tumour profile. The difference between first year
recurrence pattern, toxicity and safety of SICA was
compared in the two groups. Group A received MMC40 within 60 minutes of transurethral resection, in the
recovery room, if the surgeon believes there is no overt
perforation and bladder injury during TUR. Group B
patients only had TUR of bladder tumour.
The patients were identified from the medical
records coding and indexing6 (ICD 9 Cm) using
bladder cancer, TUR and MMC as key words.
Patients’ charts were reviewed for demographic
profile, preoperative diagnosis and imaging used,
cytological work up, tumour profile both during
cystoscopy and pre-operative imaging used, patients
records were also reviewed for all subsequent check
cystoscopies for recurrence. Any complications related
to the SICA were also noted. To assess the cost
effectiveness of SICA, the additional cost of SICA
need for over stay in recovery room was analysed and
compared with the maintenance dose of 6 cycles in out
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patient set up. The resected tumour, along with cold
cup biopsies from the tumour base and random
biopsies, if taken were sent for histopathology. The
tumour staging was done using the 1997 TNM
classification of bladder cancer. The tumour grading
was done according to the WHO/ISUP system.
Any adjuvant treatments like intravesical
chemo/immunotherapy etc. were also noted. Results
were analysed using a commercially available
statistical package, SPSS™.

RESULTS
There were 29 patients in group A and 46 in group B
(Table-1). The mean age of patient in the group A
was 55.513.7 and 53.515.8 years. There were 90%
males in group A and 89% in group B. The clinical
presentation in the two groups was similar.
Table-1. Demographic profile and presentation
Age (Years) MeanSD
Gender (M:F)
Gross haematuria (%)
Microscopic haematuria (%)
LUTS %

Group A
(n=29)

Group B
(n=46)

55.5 13.7
27:2
78
7
42
p<0.4

53.515.8
41:5
89
3
37

The cystoscopic findings (Table-2) in the two
groups showed that in group A, two third of patients
had multiple tumours whereas in group B 81% had
multiple tumours. Eighty-nine percent and 86%
tumours had papillary configuration in group A and B
respectively. Seven percent were sessile in both groups
and 4% in group A and 7% in group B had both sessile
and papillary tumours. The mean size in group A was
3.31.7 Cm and in group B it was 3.42.1 Cm.
random biopsies were taken in 22% cases in group A
and in 40% in group B.
Table-2: Cystoscopic findings
Multiple
Papillary

Group A (n=29)
33%
89%

countries, particularly in North America and Western
Europe, and in areas associated with endemic
schistosomiasis in Africa and Middle East. Bladder
cancer is more common in men than women, with a
worldwide male/female ratio of 10:3.3
Patients with superficial bladder carcinoma
can be expected to have recurrences after TUR.
Recurrence rates were reported as 30–90% according to
prognostic factors. Chemotherapeutic agents or BCG
often were administered into the bladder to prevent or
delay the recurrences.8 To date, the instillation strategy
should be chosen according to risk criteria.8-10 TUR
alone is still the standard treatment for low-risk patients,
e.g., patients with a single bladder carcinoma.11,12
However, the immediate instillation of a
chemotherapeutic agent after TUR has become an
alternative option since Oostelinck et al and Tolley et al
reported on its validity.13,14
Figure-1: Pathological evaluation of tumour
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Figure-2: Recurrence at 1st year of follow up
(p<0.04)
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Pathological evaluation (Figure-1) indicated
that 96.5% and 91% respectively were T1 cancers in
group A and B respectively. The recurrence at 1 st year
follow up showed a significant difference (p<0.04) in
the two groups (Figure-2).
The cost of single instillation of 40 mg.
MMC in the recovery room is PKR 3,000 (~50 US $)
compared to 6 cycles of MMC 20 mg in the clinic
PKR ~12,000 (~200 US $) (p<0.001).

DISCUSSION
Worldwide an estimated 356,600 new cases of bladder
cancer occur each year and, in terms of overall cancer
frequency, it is ranked as ninth.7 The highest incidence
rates are generally found in industrially developed

The therapeutic objectives in initial treatment
of superficial tumours are to remove completely the
tumour, to assess the need for further therapy and to
plan the follow-up. The EORTC Genitourinary Group
assessed the percentage of patients with recurrence at 3
months after complete resection of all visible lesions
taking into account the institution, number of tumours
at presentation and the year of treatment.2 For single
tumours, the 3-month recurrence varied from 0 to 36%
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and for multiple tumours from 7 to 75%. The 3-month
recurrence by number of tumours was 8.7% for single
tumours, 21% for 2–5 tumours and 32.2% for >5
tumours. The 3-month recurrence by year of entry for
single tumours ranged from 21.0 to 43.8% during
1975–1978, from 6.3 to 12.7% during 1984-1986 and
from 3 to 5.3% during 1987–1989. For multiple
tumours it ranged from 50.0 to 61.5% during 1975–
1978, from 20.2 to 27.3% during 1979–1983 and from
14.4 to 24.6% during 1984–1986. The use of more
refined instruments probably led to decreasing
percentage of the 3-month recurrence in more recent
years, the large variation between institutions remains
unexplained. The bladder's unique location renders its
mucosa accessible to instillation of chemotherapeutic
and immunotherapeutic agents. Cytostatics can be
instilled into the bladder hours after surgery without
severe complications. A single early instillation within
6 hours after transurethral resection (TUR) in patients
with a solitary bladder tumour category T(a)/T(1) G(1)
to G(3) could reduce the recurrence rate per year by
nearly 50%. The superiority of any of the commonly
used intravesical drugs has never been demonstrated;
the time to initiate therapy is important for treatment
outcome. Optimal results can be achieved by initiating
treatment early (within 24 hours after TUR) and for a
duration of 6 months, and maintenance (>6 months)
for patients with a delayed first instillation (>7 days
after TUR). Our study also presented the 1st year
recurrence rate as 37.4% in the controlled group and
15% in the study group.
Transurethral resection of a bladder tumour
alone has been recommended for low risk patients, but
the substantial recurrence rates affected even the lowrisk patients because they subsequently underwent
TUR-Bt again. Recently, some studies have revealed
that a single instillation immediately after TUR-Bt
prevents recurrences.13-14 Oosterlinck et al first
demonstrated that a single instillation clearly prevented
recurrence for patients with a single tumor.13 Tolley et al
stated that a single instillation can prevent recurrences of
patients with either a single or multiple tumours.14 In
this study, we demonstrated the prophylactic effect of
THP for patients with a single superficial bladder
carcinoma. The net benefit was 25.4% at 1 year, 27.0%
at 2 years and 21.5% at 3 years.14

complications. We believe that a single immediate
instillation of MMC-40 should become the standard,
which might have the advantage of excellent cost
effectiveness.

CONCLUSION
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A single immediate intravesical instillation
after TUR prevents recurrences for patients with a
single superficial bladder carcinoma, without serious
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